Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: triethyl citrate; purified talc; hypromellose; sodium stearylfumarate; glyceryl monostearate; microcrystalline cellulose; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); crospovidone; magnesium stearate; povidone; polysorbate 80; macrogol 6000; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - esomeprazole magnesium dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.69 mg - capsule, enteric - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); triethyl citrate; titanium dioxide; mannitol; hypromellose; gelatin; stearoyl macrogolglycerides; maize starch; polysorbate 80; purified talc; iron oxide yellow; sucrose; diacetylated monoglycerides; purified water; dimeticone 350; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg - tablet, enteric coated - excipient ingredients: hypromellose; purified talc; hyprolose; macrogol 6000; magnesium stearate; sodium stearylfumarate; glyceryl monostearate; triethyl citrate; microcrystalline cellulose; crospovidone; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; polysorbate 80; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: sodium stearylfumarate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; polysorbate 80; glyceryl monostearate; crospovidone; magnesium stearate; purified talc; hyprolose; macrogol 6000; triethyl citrate; hypromellose; microcrystalline cellulose; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg - tablet, enteric coated - excipient ingredients: polysorbate 80; mannitol; hyprolose; magnesium stearate; purified water; purified talc; microcrystalline cellulose; triethyl citrate; propylene glycol; methacrylic acid - ethyl acrylate copolymer (1:1); colloidal anhydrous silica; sodium lauryl sulfate; calcium hydrogen phosphate dihydrate; self-emulsifying glyceryl monostearate; crospovidone; hypromellose; titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg - tablet, enteric coated - excipient ingredients: self-emulsifying glyceryl monostearate; purified water; methacrylic acid - ethyl acrylate copolymer (1:1); hyprolose; hypromellose; polysorbate 80; sodium lauryl sulfate; triethyl citrate; magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; propylene glycol; calcium hydrogen phosphate dihydrate; mannitol; purified talc; titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg - tablet, enteric coated - excipient ingredients: purified talc; sodium lauryl sulfate; hyprolose; purified water; methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; mannitol; microcrystalline cellulose; propylene glycol; polysorbate 80; colloidal anhydrous silica; self-emulsifying glyceryl monostearate; crospovidone; magnesium stearate; calcium hydrogen phosphate dihydrate; triethyl citrate; titanium dioxide; maltodextrin; iron oxide yellow; iron oxide red; polydextrose; medium chain triglycerides - gastro-oesophageal reflux disease (gord) ,? treatment of erosive reflux oesophagitis ,? long-term management of patients with healed oesophagitis to prevent relapse ,? symptomatic treatment of gastro-oesophageal reflux disease (gord) ,? patients requiring nsaid therapy ,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug ,nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. ,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion ,in combination with appropriate antibiotics for: ,? healing of duodenal ulcer associated with helicobacter pylori ,? eradication of helicobacter pylori in patients with active or healed peptic ulcer